A significant trend for duration of use was observed for the overall, luminal A-like, and luminal B-like subtypes, with HRs increasing by 4%, 4%, and 2% per year of EPT use, respectively.
← all excerpts
Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study.
1
—
—